5-methoxytryptamine has been researched along with Disease Models, Animal in 9 studies
5-Methoxytryptamine: Serotonin derivative proposed as potentiator for hypnotics and sedatives.
5-methoxytryptamine : A member of the class of tryptamines that is the methyl ether derivative of serotonin.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perinatal administration of serotonin (5HT) agonist 5-methoxytryptamine (5MT) induces developmental hyperserotonemia (DHS; elevated blood serotonin) and produces behavioral and neurochemical changes in rats relevant to Autism Spectrum Disorder (ASD), such as oxytocin dysregulation." | 7.88 | Serotonin receptor regulation as a potential mechanism for sexually dimorphic oxytocin dysregulation in a model of Autism. ( Edwards, KA; Madden, AMK; Zup, SL, 2018) |
| "Perinatal administration of serotonin (5HT) agonist 5-methoxytryptamine (5MT) induces developmental hyperserotonemia (DHS; elevated blood serotonin) and produces behavioral and neurochemical changes in rats relevant to Autism Spectrum Disorder (ASD), such as oxytocin dysregulation." | 3.88 | Serotonin receptor regulation as a potential mechanism for sexually dimorphic oxytocin dysregulation in a model of Autism. ( Edwards, KA; Madden, AMK; Zup, SL, 2018) |
| "Melatonin has been shown to prevent the progressive degeneration produced by neurotoxins employed in experimental models to mimic the degenerative events in various neuropsychiatric disease states." | 2.43 | The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease. ( Willis, GL, 2005) |
| "Autism is classified as a pervasive developmental disorder, with several cardinal features including sensory disturbances, obsessive-compulsive-like behavior, lack of bonding to caregivers and motor disturbances." | 1.31 | Behavioral and magnetic resonance spectroscopic studies in the rat hyperserotonemic model of autism. ( Borella, A; Huang, W; Johnstone, F; Kahne, D; Shapiro, L; Tudorica, A; Whitaker-Azmitia, PM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Edwards, KA | 1 |
| Madden, AMK | 1 |
| Zup, SL | 1 |
| Horvath, G | 1 |
| Joo, G | 1 |
| Kekesi, G | 1 |
| Farkas, I | 1 |
| Tuboly, G | 1 |
| Petrovszki, Z | 1 |
| Benedek, G | 1 |
| Willis, GL | 2 |
| Kennedy, GA | 1 |
| Bravo, G | 1 |
| Ibarra, A | 1 |
| Guizar-Sahagún, G | 1 |
| Rojas, G | 1 |
| Hong, E | 1 |
| Teramoto, Y | 1 |
| Urano, T | 1 |
| Nagai, N | 1 |
| Takada, Y | 1 |
| Ikeda, K | 1 |
| Takada, A | 1 |
| Kahne, D | 1 |
| Tudorica, A | 1 |
| Borella, A | 1 |
| Shapiro, L | 1 |
| Johnstone, F | 1 |
| Huang, W | 1 |
| Whitaker-Azmitia, PM | 1 |
2 reviews available for 5-methoxytryptamine and Disease Models, Animal
| Article | Year |
|---|---|
The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dose-Response | 2004 |
The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Melato | 2005 |
7 other studies available for 5-methoxytryptamine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Serotonin receptor regulation as a potential mechanism for sexually dimorphic oxytocin dysregulation in a model of Autism.
Topics: 5-Methoxytryptamine; Animals; Autism Spectrum Disorder; Autistic Disorder; Disease Models, Animal; F | 2018 |
Inhibition of itch-related responses at spinal level in rats.
Topics: 5-Methoxytryptamine; Analgesics; Animals; Behavior, Animal; Disease Models, Animal; Drug Interaction | 2011 |
Indorenate improves motor function in rats with chronic spinal cord injury.
Topics: 5-Methoxytryptamine; Animals; Chronic Disease; Contusions; Disease Models, Animal; Exploratory Behav | 2007 |
Plasma levels of 5-HT and 5-HIAA increased after intestinal ischemia/reperfusion in rats.
Topics: 5-Methoxytryptamine; Animals; Dioxanes; Disease Models, Animal; Hydroxyindoleacetic Acid; Intestines | 1998 |
Behavioral and magnetic resonance spectroscopic studies in the rat hyperserotonemic model of autism.
Topics: 5-Methoxytryptamine; Acoustic Stimulation; Animals; Autistic Disorder; Behavior, Animal; Birth Weigh | 2002 |